- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03098238
Endothelial Microparticules and Antibody Mediated Rejection and Kidney Transplantation: Biomarker of Antibody-mediated Rejection in Kidney Transplantation (MICROMARK RJ)
Endothelial Microparticules as Biomarker of Antibody-mediated Rejection in Kidney Transplantation
Context and rationale:
Antibody-mediated rejection is the leading cause of long-term renal graft loss. It's due to the production by the recipient of antibodies directed against antigens (belonging or not to the HLA system) present on the surface of the donor specific endothelial cells (DSA), leading to graft failure.
The main difficulty to manage the humoral rejection is the delay of the diagnosis and the treatment to slow the evolution towards fibrosis.
Positivity of anti-HLA antibodies is the main risk factor for the rejection but the only way to make the diagnosis of humoral rejection is to perform a graft biopsy, an invasive process.
Endothelial microparticles (MPE) are small membrane vesicles generated by endothelial cell activation and / or apoptosis processes.
We test the hypothesis that endothelial microparticles are an early diagnostic biomarker of humoral rejection in renal transplantation allowing to detect it at the "subclinical" stage.
Primary and secondary objectives:
The main objective of this study is to estimate the performance of MPE plasma concentration for the diagnosis of humoral rejection in renal transplant patients with DSA. The secondary objective is to investigate by mass spectrometry the MPEs specific to the endothelium of the graft and to evaluate their diagnostic performance in relation to non-specific MEPs
Methodology :
We will conduct a cross-sectional evaluation of a diagnostic method from a collection of biological samples. The gold standard for the diagnosis of humoral rejection is the histological diagnosis on graft biopsy. The new test under study will be the flow cytometric assay of the MPE concentration carried out on plasma taken on the day of the graft biopsy.
Feasibility:
Among the active list of renal transplant patients attending the Montpellier University Hospital, we estimate that we can include the number of subjects required (N = 250) over 18 months. This work will be carried out in a laboratory with all the tools and techniques used, in particular flow cytometry and mass spectrometry, perfectly mastered and realized on dedicated technical platforms
Benefits / Outlook:
find a non-invasive early diagnostic biomarker to detect humoral rejection from the "subclinical" stage in order to set up an adapted treatment as quickly as possible.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Context and rationale:
Antibody-mediated rejection is the leading cause of long-term renal graft loss. It's due to the production by the recipient of antibodies directed against antigens (belonging or not to the HLA system) present on the surface of the donor specific endothelial cells (DSA), the binding of which can activate the renal endothelium and be responsible for inflammation leading to fibrosis and graft destruction.
The main obstacle in the management of the humoral rejection is the delay of the diagnosis and the treatment to slow the evolution towards fibrosis. At the beginning of the process there is no "apparent" dysfunction of the graft (elevation of serum creatinine and / or proteinuria) but only inflammation of the renal parenchyma: this is referred to as "subclinical" humoral rejection. Graft dysfunction occurs only when the inflammation is serious and responsible for irreversible lesions of fibrosis.
New sensitive detection techniques for anti-HLA antibodies allow to detect DSA well before the onset of humoral rejection but the only way to make the diagnosis of humoral rejection is to perform a graft biopsy, an invasive process with a hemorrhagic risk which can not be repeated too frequently.
Endothelial microparticles (MPE) are small membrane vesicles generated by endothelial cell activation and / or apoptosis processes. An increasing level in circulating blood appears today as a endothelial dysfunction in many pathologies. Their role in humoral rejection, a model of endothelial dysfunction, has never been explored.
We wish to test the hypothesis that endothelial microparticles are an early diagnostic biomarker of humoral rejection in renal transplantation allowing to detect it at the "subclinical" stage.
Primary and secondary objectives:
The main objective of this study is to estimate the performance of MPE plasma concentration for the diagnosis of humoral rejection in renal transplant patients with DSA. The secondary objective is to investigate by mass spectrometry the MPEs specific to the endothelium of the graft and to evaluate their diagnostic performance in relation to non-specific MEPs
Methodology :
We will conduct a cross-sectional evaluation of a diagnostic method from a collection of biological samples. The gold standard for the diagnosis of humoral rejection is the histological diagnosis on graft biopsy. The new test under study will be the flow cytometric assay of the MPE concentration carried out on plasma taken on the day of the graft biopsy.
Feasibility:
Among the active list of renal transplant patients attending the Montpellier University Hospital, we estimate that we can include the number of subjects required (N = 250) over 18 months. This work will be carried out in a laboratory with all the tools and techniques used, in particular flow cytometry and mass spectrometry, perfectly mastered and realized on dedicated technical platforms
Benefits / Outlook:
At a time when the shortage of organs is growing and becomes a real public health problem, it becomes essential to better control the management of humoral rejection, the main cause of long-term renal graft loss. One of the key steps in this step is to find a non-invasive early diagnostic biomarker to detect humoral rejection from the "subclinical" stage in order to set up an adapted treatment as quickly as possible.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- UHMontpellier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age greater than or equal to 18 years at time of inclusion
- Renal transplant patients monitored at Montpellier University Hospital
- With a recent or planned realization of a graft biopsy
- Patients with DSA (s) detected by Single Antigen Bead Assay (SAB, LabScreen Single Antigen, One Lambda Kit) with an average fluorescence intensity> 500 IU Or Patients without DSA transplanted to a year with a systematic biopsy aspiration.
Exclusion Criteria:
- Refusal to participate in or to undergo the examination
- Major protected by guardianship
- History of treated humoral rejection
- Incompatible graft ABO
- Multi-organ transplantation
- Cardiovascular disease active (myocardial infarction <3 months, arteriopathy obliterating lower limbs stage III or IV)
- Sepsis in progress
- Evolving Cancers
- Lupus nephropathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Patients without humoral rejection or DSA
Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
|
Biological sampling of two citrate tubes (18 ml) during a normal blood
|
Other: Patient without humoral rejection with a DSA
Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
|
Biological sampling of two citrate tubes (18 ml) during a normal blood
|
Other: Patients with humoral rejection
|
Biological sampling of two citrate tubes (18 ml) during a normal blood
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration of endothelial microparticles
Time Frame: 1 day
|
Endothelial microparticle (MPE) plasma concentration for the diagnosis of humoral rejection in renal transplant patients with DSA.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of specific MEPs
Time Frame: 1 day
|
Presence of MPEs specific to the graft endothelium and to evaluate their diagnostic performance in relation to non-specific MEPs
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Moglie LE QUINTREC DONNETTE, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RECHMPL16_0263
- UF 9746 (Other Identifier: Montpellier University Hospital)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)Active, not recruitingKidney Transplantation | Renal Transplantation | Renal Transplant RecipientUnited States
-
Astellas Pharma Korea, Inc.CompletedKidney Transplantation | Renal Transplantation | Stable Renal RecipientsKorea, Republic of
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
NovartisCompletedOrgan Transplantation, Renal Transplantation
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationTerminatedKidney Transplantation | Renal TransplantationUnited States
-
University of North Carolina, Chapel HillMallinckrodtWithdrawnKidney Transplantation | Renal Transplantation | FSGSUnited States
-
Bristol-Myers SquibbCompletedKidney Transplantation | Graft Rejection | Renal TransplantationUnited States
-
Rabin Medical CenterRecruitingRenal TransplantationIsrael
Clinical Trials on Biological sample
-
Diaccurate SASCIC 1417 Cochin-PasteurRecruiting
-
University Hospital, LilleRecruitingEosinophilia | Hypereosinophilic SyndromeFrance
-
New York Stem Cell Foundation Research InstituteSilverstein FoundationRecruitingHealthy | Parkinson Disease | Gaucher Disease | GBA Gene MutationUnited States
-
University Hospital, BrestNot yet recruitingRepeated Spontaneous Miscarriages | Fetal Deaths in UteroFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; ScreenCell; Celen... and other collaboratorsUnknownMelanoma | Circulating Tumor CellFrance
-
Institut Hospitalo-Universitaire Méditerranée InfectionUniversity Hospital, MarseilleUnknown
-
New York Stem Cell Foundation Research InstituteRecruitingPTSD | Multiple Sclerosis | Cervical Cancer | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Macular Degeneration | Diabetes Mellitus, Type 1 | Parkinson Disease | Amyotrophic Lateral Sclerosis | Dementia | Ovarian Cancer | Alzheimer Disease | ALS | Vulvar Cancer | Post Traumatic Stress Disorder | Lewy Body Disease and other conditionsUnited States
-
New York Stem Cell Foundation Research InstituteCharcot-Marie-Tooth AssociationRecruitingHealthy | Charcot-Marie-Tooth DiseaseUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Catholic University of the Sacred Heart; Heinrich-Heine University, Duesseldorf and other collaboratorsRecruitingGlioblastoma | Glioma, MalignantItaly